S-1: GRI Bio Eyes Public Offering to Fuel Clinical Programs, Address Nasdaq Compliance

GRI Bio, a clinical-stage biopharmaceutical company, files an S-1 registration statement for a public offering of common stock and warrants to fund its clinical programs and address Nasdaq's listing requirements.

Summary

• GRI Bio, Inc., a clinical-stage biopharmaceutical company, has filed a Form S-1 registration statement for a proposed public offering.
• The offering includes shares of common stock and accompanying warrants, as well as pre-funded warrants and placement agent warrants.
• The company intends to use the net proceeds for working capital, product candidate development activities, and general corporate purposes.
• GRI Bio is focused on developing therapies for inflammatory, fibrotic, and autoimmune disorders, with its lead product candidate, GRI-0621, targeting idiopathic pulmonary fibrosis (IPF).
• The company expects interim data from its Phase 2a biomarker study of GRI-0621 in the third quarter of 2024 and topline results in the fourth quarter of 2024.
• The offering is being conducted on a best efforts basis through H.C. Wainwright & Co., LLC, as the exclusive placement agent.
• GRI Bio's common stock is listed on The Nasdaq Capital Market under the symbol GRI.
• The company is currently not in compliance with Nasdaq's minimum stockholders' equity requirement and has a hearing scheduled for July 11, 2024, to appeal a staff determination letter.
• The company also received a letter from Nasdaq indicating that it no longer meets the Minimum Bid Price Rule and has until July 3, 2024, to regain compliance.
• The company has effected reverse stock splits in January 2024 and June 2024 to attempt to regain compliance with the Minimum Bid Price Rule.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is advancing its clinical programs, it faces significant financial challenges and regulatory hurdles, including Nasdaq compliance issues. The need for additional capital and the going concern warning from auditors contribute to a negative outlook.

Positives

• The company has a lead product candidate, GRI-0621, in Phase 2a clinical trials for IPF, with interim data expected in Q3 2024 and topline results in Q4 2024.
• The company is also developing GRI-0803 for autoimmune disorders, with plans to file an IND for a Phase 1 trial in SLE in the second half of 2024.
• The company has a proprietary library of 500+ compounds.
• The company has received authorization of its clinical trial application (CTA) from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK.

Negatives

• The company is not currently in compliance with Nasdaq's minimum stockholders' equity requirement and has a hearing scheduled for July 11, 2024, to appeal a staff determination letter.
• The company also received a letter from Nasdaq indicating that it no longer meets the Minimum Bid Price Rule and has until July 3, 2024, to regain compliance.
• The company has incurred significant net losses since inception and expects to continue to incur significant net losses for the foreseeable future.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company has broad discretion to determine how to use the funds raised in this offering and may use them in ways that may not enhance its operating results or the price of its Common Stock.

Risks

• The company may not raise the amount of capital it believes is required for its business plans, including its near-term business plans.
• The company will require substantial additional capital in addition to any proceeds from this offering to finance its operations and to potentially regain compliance with the Stockholders Equity Requirement.
• The company's business is highly dependent on the success of its lead product candidate, GRI-0621, and any other product candidates that it may advance into clinical development.
• The company relies on third parties to conduct its clinical trials, manufacture its product candidates and perform other services.
• The company may be unable to adequately protect its information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage its reputation, and subject it to significant financial and legal exposure.
• The June 2024 Reverse Stock Split could cause the company's stock price to decline relative to its value before the split and decrease the liquidity of shares of its Common Stock.

Future Outlook

The company expects to use the net proceeds from this offering for working capital, product candidate development activities, and general corporate purposes. The company expects interim data from its Phase 2a biomarker study of GRI-0621 in the third quarter of 2024 and topline results in the fourth quarter of 2024. The company expects to file an IND with respect to this Phase 1a and 1b trial in the second half of 2024.

Industry Context

The biopharmaceutical industry is characterized by rapid technological advancements and intense competition. GRI Bio faces competition from established pharmaceutical companies and smaller biotechnology firms in the development of therapies for inflammatory, fibrotic, and autoimmune disorders.

Comparison to Industry Standards

• GRI Bio's approach of targeting NKT cells is novel, as there are currently no approved therapies that specifically target these cells.
• Existing IPF therapies, such as nintedanib (OFEV) and pirfenidone (Esbriet), have limitations in terms of overall survival and side effects, creating an opportunity for GRI-0621.
• The company's focus on SLE and lupus nephritis addresses a significant unmet need, as only two drugs have been approved for lupus in the past 50 years.
• Competitors in the IPF space include AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis, while competitors in the SLE space include Astellas Pharma, AstraZeneca, Aurinia Pharmaceuticals, Biogen, GlaxoSmithKline, Johnson & Johnson, Nektar Therapeutics, Roche Holding, Sanofi SA, and UCB S.A.

Stakeholder Impact

• Shareholders will experience dilution as a result of the public offering.
• Shareholders face the risk of a decline in stock price due to market volatility and potential delisting from Nasdaq.
• Employees' job security is uncertain due to the company's financial challenges and potential need to reduce operations.
• Patients with IPF and autoimmune disorders may benefit from the development of new therapies, but the success of these therapies is not guaranteed.
• Creditors face the risk of non-payment if the company is unable to secure additional funding and continue as a going concern.

Next Steps

• Complete the public offering of common stock and warrants.
• Continue Phase 2a clinical trials of GRI-0621 for IPF and report interim and topline data.
• File an IND for a Phase 1 trial of GRI-0803 in SLE.
• Appeal Nasdaq's staff determination letter regarding stockholders' equity requirement.
• Regain compliance with Nasdaq's Minimum Bid Price Rule.

Key Dates

Keywords

GRI Bio, public offering, common stock, warrants, pre-funded warrants, placement agent, clinical trials, IPF, GRI-0621, GRI-0803, Nasdaq, compliance, biopharmaceutical, autoimmune disorders, fibrotic diseases